For patients who had at least 1 year of follow up after stopping antibiotics (pulmonary n = 21, non-pulmonary n = 14), 43% of patients with pulmonary infections achieved clinical cure and 79% of patients with non-pulmonary infections achieved clinical cure. Within 1 year of follow-up 19% of pulmonary infection patients and none of the non-pulmonary patients had died. Conclusion. As a part of multidrug therapy, CFZ is useful in the in the treatment of drug-resistant RGM infections, particularly skin infections, and offers a better tolerated option compared with other available antibiotics. Disclosures. All authors: No reported disclosures.